Sirolimus-eluting stents for the treatment of bare-metal in-stent restenosis: Long-term clinical follow up

Journal of Invasive Cardiology

Volumn 19, Issue 4, 2007, Pages 174-180

  Sheiban, Imad ^a   Chiribiri, Amedeo ^b   Beninati, Serena ^b   Moretti, Claudio ^b   Omede, Pierluigi ^b   Sciuto, Filippo ^b   Marra, Walter Grosso ^b   Biondi Zoccai, Giuseppe ^b   Bollati, Mario ^b   Gambino, Alfonso ^b   Trevi, Gian Paolo ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

RAPAMYCIN;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CORONARY ARTERY BYPASS GRAFT; DATA ANALYSIS; DEATH; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; IMPLANT; IN-STENT RESTENOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; REVASCULARIZATION; STROKE; THROMBOSIS;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ANGIOGRAPHY; CORONARY DISEASE; CORONARY RESTENOSIS; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; SIROLIMUS; STENTS;

EID: 34147189952     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Chen MS, John JM, Chew DP, et al. Bare metal stent restenosis is not a benign clinical entity. Am Heart J 2006;151:1260-1364.
2. Lemos PA, Serruys PW, van Domburg RT, et al. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world": The Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation 2004;109:190-195.
3. Kasaoka S, Tobis JM, Akiyama T, et al. Angiographic and intravascular ultrasound predictors of in-stent restenosis. J Am Coll Cardiol 1998;32:1630-1365.
4. Kastrati A, Schomig A, Elezi S, et al. Interlesion dependence of the risk for restenosis in patients with coronary stent placement in multiple lesions. Circulation 1998;97:2396-2401.
5. Elezi S, Kastrati A, Neumann FJ, et al. Vessel size and long term outcome after coronary stent placement. Circulation 1998;98:1875-1880.
6. Akiyama T, Moussa I, Reimers B, et al. Angiographic and clinical outcome following coronary stenting of small vessels. A comparison with coronary stenting of larger vessels. J Am Coll Cardiol 1998;32:1610-1618.
7. Agostoni P, Biondi-Zoccai GG, Gasparini GL, et al. Is bare-metal stenting superior to balloon angioplasty for small vessel coronary artery disease? Evidence from a meta-analysis of randomized trials. Eur Heart J 2005;26:881-889.
8. Hoffmann R, Mintz GS, Mehran R, et al. Intravascular ultrasound predictors of angiographic restenosis in lesions treated with Palmaz-Schatz stents. J Am Coll Cardiol 1998;31:43-49.
9. Holmes DR Jr, Savage M, LaBlanche JM, et al. Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation 2002;106:1243-1250.
10. Albiero R, Silber S, Di Mario C, et al. RESCUT Investigators. Cutting balloon versus conventional balloon angioplasty for the treatment of in-stent restenosis: Results of the restenosis cutting balloon evaluation trial (RESCUT). J Am Coll Cardiol 2004;43:943-939.
11. Alfonso F, Melgares R, Mainar V, et al. Restensois Intra-stent: Balloon angioplasty versus elective Stenting (RIBS) Investigators. Therapeutic implications of in-stent restenosis located at the stent edge. Insights from the restenosis intra-stent balloon angioplasty versus elective stenting (RIBS) randomized trial. Eur Heart J 2004;25:1829-1835.
12. Waksman R, Ajani AE, White RL, et al. Five-year follow-up after intracoronary gamma radiation therapy for in-stent restenosis. Circulation 2004;109:340-344.
13. Parenti DZ, Marsico F, Tosi G, et al. Intracoronary beta-radiation for the treatment of patients at very high risk for recurrence of in-stent restenosis: A single center experience. Ital Heart J 2003;4:199-204.
14. Kastrati A, Mehilli J, von Beckerath N, et al. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: A randomized controlled trial. JAMA 2005;293:165-171.
15. Holmes DR Jr, Teirstein P, Satler L, et al. SISR Investigators. Sirolimus-eluting stents versus vascular brachytherapy for in-stent restenosis within bare-metal stents: The SISR randomized trial. JAMA 2006;295:1264-1273.
16. Stone GW, Ellis SG, O'Shaughnessy CD, et al. TAXUS V ISR Investigators. Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: The TAXUS V ISR randomized trial. JAMA 2006;295:1253-1263.
17. Saia F, Lemos PA, Arampatzis CA, et al. Routine sirolimus-eluting stent implantation for unselected in-stent restenosis: Insights from the rapamycin-eluting stent evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry. Heart 2004;90:1183-1188.
18. Liistro F, Fineschi M, Angioli P, et al. Effectiveness and safety of sirolimus stent implantation for coronary in-stent restenosis: The TRUE (Tuscany Registry of Sirolimus for Unselected In-Stent Restenosis) Registry. J Am Coll Cardiol 2006;48:270-275.
19. Biondi-Zoccai GG, Sangiorgi GM, Chieffo A, et al. RECIPE (Real-world Eluting-stent Comparative Italian retrosPective Evaluation) study investigators. Validation of predictors of intraprocedural stent thrombosis in the drug-eluting stent era. Am J Cardiol 2005;95:1466-1468.
20. Mehran R, Dangas G, Abizaid AS, et al. Angiographic patterns of in-stent restenosis: Classification and implications for long-term outcome. Circulation 1999;100:1872-1878.
21. Nordmann AJ, Briel M, Bucher HC. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: A meta-analysis. Eur Heart J 2006;27:2784-2814.
22. Kaiser C, Brunner-La Rocca HP, Buser PT, et al. BASKET Investigators. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: Randomized Basel Stent Kosten Effektivitats Trial (BASKET). Lancet 2005;366:921-929.
23. Sousa JE, Costa MA, Abizaid A, et al. Sirolimus-eluting stent for the treatment of in-stent restenosis: A quantitative coronary angiography and three dimensional intravascular ultrasound study. Circulation 2003;107:24-27.
24. Tanabe K, Serruys PW, Grube E, et al. TAXUS III Trial: In-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation 2003;107:559-564.
25. Airoldi F, Briguori C, Iakovou I, et al. Comparison of sirolimus versus paclitaxel eluting stents for treatment of coronary in-stent restenosis. Am J Cardiol 2006;97:1182-1187.
26. Cosgrave J, Melzi G, Biondi-Zoccai GG, et al. Drug-eluting stent restenosis the pattern predicts the outcome. J Am Coll Cardiol 2006;47:2399-2404.
27. Commeau P, Barragan PT, Roquebert PO, Simeoni JB. ISR II study: A long-term evaluation of sirolimus-eluting stent in the treatment of patients with in-stent restenotic native coronary artery lesions. Catheter Cardiovasc Interv 2005;66:158-162.
28. Blackman DJ, Porto I, Shirodaria C, et al. Usefulness of high-pressure post-dilatation to optimize deployment of drug-eluting stents for the treatment of diffuse in-stent coronary restenosis. Am J Cardiol 2004;94:922-925.
29. McFadden EP, Stabile E, Regar E, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004;364:1519-1521.
30. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293:2126-2130.
31. Ong AT, McFadden EP, Regar E, et al. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol 2005;45:2088-2092.
32. Degertekin M, Regar E, Tanabe K, et al. Sirolimus-eluting stent for treatment of complex in-stent restenosis: The first clinical experience. J Am Coll Cardiol 2003;41:184-189.
33. Biondi-Zoccai GGL, Agostoni P, Abbate A. Parallel hierarchy of scientific studies in cardiovascular medicine. Ital Heart J 2003;4:819-820.
34. Windecker S, Remondino A, Eberli FR, et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med 2005;353:653-662.